Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

1.

Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells.

Chiovaro F, Martina E, Bottos A, Scherberich A, Hynes NE, Chiquet-Ehrismann R.

Int J Cancer. 2015 Apr 13. doi: 10.1002/ijc.29565. [Epub ahead of print]

PMID:
25868708
2.

Cancer: Staying together on the road to metastasis.

Bottos A, Hynes NE.

Nature. 2014 Oct 16;514(7522):309-10. doi: 10.1038/514309a. No abstract available.

PMID:
25318518
3.

Memo is a copper-dependent redox protein with an essential role in migration and metastasis.

MacDonald G, Nalvarte I, Smirnova T, Vecchi M, Aceto N, Dolemeyer A, Frei A, Lienhard S, Wyckoff J, Hess D, Seebacher J, Keusch JJ, Gut H, Salaun D, Mazzarol G, Disalvatore D, Bentires-Alj M, Di Fiore PP, Badache A, Hynes NE.

Sci Signal. 2014 Jun 10;7(329):ra56. doi: 10.1126/scisignal.2004870.

PMID:
24917593
4.

Memo has a novel role in S1P signaling and is [corrected] crucial for vascular development.

Kondo S, Bottos A, Allegood JC, Masson R, Maurer FG, Genoud C, Kaeser P, Huwiler A, Murakami M, Spiegel S, Hynes NE.

PLoS One. 2014 Apr 8;9(4):e94114. doi: 10.1371/journal.pone.0094114. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e101351.

5.

EGF receptor family: twisting targets for improved cancer therapies.

Burgess AW, Henis YI, Hynes NE, Jovin T, Levitzki A, Pinkas-Kramarski R, Yarden Y.

Growth Factors. 2014 Apr;32(2):74-81. doi: 10.3109/08977194.2014.896355. Epub 2014 Mar 18.

PMID:
24641597
7.

Loss of Memo, a novel FGFR regulator, results in reduced lifespan.

Haenzi B, Bonny O, Masson R, Lienhard S, Dey JH, Kuro-o M, Hynes NE.

FASEB J. 2014 Jan;28(1):327-36. doi: 10.1096/fj.13-228320. Epub 2013 Sep 20.

8.

Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.

Gattelli A, Nalvarte I, Boulay A, Roloff TC, Schreiber M, Carragher N, Macleod KK, Schlederer M, Lienhard S, Kenner L, Torres-Arzayus MI, Hynes NE.

EMBO Mol Med. 2013 Sep;5(9):1335-50. doi: 10.1002/emmm.201302625. Epub 2013 Jul 19.

9.

Signalling change: signal transduction through the decades.

Hynes NE, Ingham PW, Lim WA, Marshall CJ, Massagué J, Pawson T.

Nat Rev Mol Cell Biol. 2013 Jun;14(6):393-8. doi: 10.1038/nrm3581. Epub 2013 May 2. Review.

PMID:
23636498
10.

Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.

Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH, Hynes NE.

Breast Cancer Res. 2013 Jan 23;15(1):R8. doi: 10.1186/bcr3379.

11.

Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth.

Tarkkonen KM, Nilsson EM, Kähkönen TE, Dey JH, Heikkilä JE, Tuomela JM, Liu Q, Hynes NE, Härkönen PL.

PLoS One. 2012;7(11):e49970. doi: 10.1371/journal.pone.0049970. Epub 2012 Nov 21.

12.

Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.

Wöhrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M, Graus Porta D.

J Bone Miner Res. 2013 Apr;28(4):899-911. doi: 10.1002/jbmr.1810.

PMID:
23129509
13.

Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.

Aceto N, Duss S, MacDonald G, Meyer DS, Roloff TC, Hynes NE, Bentires-Alj M.

Breast Cancer Res. 2012 Oct 12;14(5):R131. doi: 10.1186/bcr3329.

14.

The 14-3-3σ tumor suppressor has multiple functions in ErbB2-induced breast cancer.

Hynes NE, Smirnova T.

Cancer Discov. 2012 Jan;2(1):19-22. doi: 10.1158/2159-8290.CD-11-0317.

15.

MHO1, an evolutionarily conserved gene, is synthetic lethal with PLC1; Mho1p has a role in invasive growth.

Schlatter ID, Meira M, Ueberschlag V, Hoepfner D, Movva R, Hynes NE.

PLoS One. 2012;7(3):e32501. doi: 10.1371/journal.pone.0032501. Epub 2012 Mar 7.

16.

FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone.

Wöhrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, Müller M, Kinzel B, Thuery A, Brueggen J, Hynes NE, Sellers WR, Hofmann F, Graus-Porta D.

J Bone Miner Res. 2011 Oct;26(10):2486-97. doi: 10.1002/jbmr.478.

PMID:
21812026
17.

Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.

Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, Coniglio SJ, Backer JM, Bresnick AR, Condeelis JS, Hynes NE, Segall JE.

Oncogene. 2012 Feb 9;31(6):706-15. doi: 10.1038/onc.2011.275. Epub 2011 Jul 4.

18.

P-Rex1, a guanine exchange factor that is overexpressed in breast cancer, is a convergence node for ErbB and CXCR4 signaling.

Hynes NE, Gattelli A.

Mol Cell. 2011 Jan 7;41(1):5-7. doi: 10.1016/j.molcel.2010.12.024.

19.

Unfavorable drug interactions in targeted breast cancer therapy.

Groner B, Hynes NE.

Cancer Cell. 2010 Nov 16;18(5):401-2. doi: 10.1016/j.ccr.2010.10.027. No abstract available.

20.

Potential for targeting the fibroblast growth factor receptors in breast cancer.

Hynes NE, Dey JH.

Cancer Res. 2010 Jul 1;70(13):5199-202. doi: 10.1158/0008-5472.CAN-10-0918. Epub 2010 Jun 22. Review. Erratum in: Cancer Res. 2010 Oct 1;70(19):7734.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk